logo
Share SHARE
FONT-SIZE Plus   Neg

Express Scripts Closes $29.1 Bln Medco Health Solutions Acquisition -Quick Facts

Express Scripts (ESRX) completed its $29.1 billion acquisition of Medco Health Solutions. The new Express Scripts combines clinical expertise and innovative applications of behavioral science to enhance patient health while driving down the cost of healthcare. Combining the companies' complementary offerings would create better models of care and improve patients' adherence to prescribed treatment regimens.

Commenting on the merger, George Paz, chairman and chief executive officer, Express Scripts stated, "It represents the next chapter of our mission to lower costs, drive out waste in healthcare and improve patient health. We remain focused on formulary management, channel management and closing gaps in care, which will allow us to further improve the health of people with chronic and complex medical conditions."

Following consummation of the purchase, each share of pre-closing Medco common stock was converted into the right to receive $28.80 in cash, without interest and 0.81 common shares of the new Express Scripts, a holding company which would own 100% of each of the existing Express Scripts and Medco, and each share of the pre-closing Express Scripts common stock was converted into one share of new Express Scripts common stock.

As already announced, the company expects synergies of $1 billion once fully integrated, representing nearly 1 percent of the combined company's costs. The transaction is expected to be slightly accretive to earnings per share, excluding integration and deal-related costs and charges, in the first full year after closing and moderately accretive once fully integrated.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
ConAgra Foods Inc. (CAG) reported a net income attributable to the company for the fourth quarter ended May 29, 2016 that declined 43.8 percent from last year. Adjusted earnings per share from continuing operations decreased 5% from the prior year. The comparable earnings per share decline reflected... Another busy month on the FDA calendar has gone by but not without its fair share of hurrahs and heartaches. This is not unexpected, given the uncertainties characterizing drug development and approval processes, which in turn manifest as volatility in stocks belonging to the biotech space. German sporting goods giant Adidas Group (ADDYY.PK, ADDDF.PK) extended its long-term relationship with rapper and fashion designer Kanye West, launching a new line of Yeezy brand products for all genders, the company stated. adidas + Kanye West offers Yeezy branded footwear, apparel and accessories for all genders. Under the deal, West will join with adidas team to lead the development...
comments powered by Disqus
Follow RTT